Standing up in public for a broader conception of value in healthcare.

25-32 of 72 News

viewpoint 4/14/17

In Health Affairs: Balancing the Use of Cost-Effectiveness Analysis in Healthcare Innovations IVI's Peter Neumann and James Baumgardner examine the reasons why the application of CEA technologies across different types of healthcare interventions are imbalanced, and suggest some possible ways in which the policies of government and private entities might change to address the issue. READ MORE

viewpoint 4/12/17

On the Health Affairs Blog: Assessing the Value of Treatments for Rare Diseases Presents Several Unique Challenges IVI's Darius Lakdawalla and Anupam Jena argue it's essential that value frameworks consider the potentially unique aspects of value that rare disease treatments provide. READ MORE

viewpoint 4/07/17

On the Health Affairs Blog: Rachel Sachs Summarizes Scott Gottlieb's FDA Commissioner Confirmation Hearing Calling it "remarkably unremarkable," Rachel Sachs summarizes Scott Gottlieb's recent FDA Commissioner confirmation hearing. READ MORE

viewpoint 4/05/17

On the Health Affairs Blog: Silver Suggests Patent Buyouts and Licensing Changes As Strategy For Lowering Brand Drug Prices Jonathan Silver examines patent buyouts and licensing as a novel strategy for lowering branded drug prices. READ MORE

viewpoint 4/03/17

On the Health Affairs Blog: Fox and Watrous Cite Lessons Learned from Genentech-Priority Health Pilot in Illustrating Outcomes-Based Contracting Challenges John Fox and Marc Watrous use the 2015' Genentech-Priority Health Pilot as a case study in the challenges presented in outcomes-based contracting. READ MORE

viewpoint 4/03/17

On the Health Affairs Blog: Blumenthal, Linthicum and Kamal-Bahl Address Outcomes-Based Pricing Agreements Daniel Blumenthal, Mark Linthicum, and Sachin Kamal-Bahl outline the key challenges and strategies surrounding the establishment of outcomes-based pricing agreements. READ MORE

viewpoint 3/31/17

On the Health Affairs Blog: Horn and Dickson Offer Proposals to Modernize and Strengthen Drug Pricing Regulations Tim Horn and Sean Dickson offer four proposals for strengthening existing regulations to reduce drug prices while incentivizing scientific ingenuity and discovery. READ MORE

viewpoint 3/23/17

On the Health Affairs Blog: Avorn Assesses the Landscape for Prescription Drug Regulation, Promotion, and Advocacy Jerry Avorn provides a summary of the year's developments in health law, focusing on the 21st Century Cures Act, the appointment of a new FDA Commissioner, and "academic detailing." READ MORE